thalidomide has been researched along with Hypertrophy, Left Ventricular in 2 studies
Thalidomide: A piperidinyl isoindole originally introduced as a non-barbiturate hypnotic, but withdrawn from the market due to teratogenic effects. It has been reintroduced and used for a number of immunological and inflammatory disorders. Thalidomide displays immunosuppressive and anti-angiogenic activity. It inhibits release of TUMOR NECROSIS FACTOR-ALPHA from monocytes, and modulates other cytokine action.
thalidomide : A racemate comprising equimolar amounts of R- and S-thalidomide.
2-(2,6-dioxopiperidin-3-yl)-1H-isoindole-1,3(2H)-dione : A dicarboximide that is isoindole-1,3(2H)-dione in which the hydrogen attached to the nitrogen is substituted by a 2,6-dioxopiperidin-3-yl group.
Hypertrophy, Left Ventricular: Enlargement of the LEFT VENTRICLE of the heart. This increase in ventricular mass is attributed to sustained abnormal pressure or volume loads and is a contributor to cardiovascular morbidity and mortality.
| Excerpt | Relevance | Reference |
|---|---|---|
| "Echocardiography detected left ventricular hypertrophy and diastolic dysfunction." | 1.39 | Pulmonary hypertension and refractory heart failure in a patient with Crow-Fukase (POEMS) syndrome. ( Hisa, S; Kanno, Y; Kobayashi, A; Mizukami, H; Nakazato, K; Noji, H; Ogawa, K; Ohkawara, H; Saitoh, S; Shichishima-Nakamura, A; Suzuki, H; Takahashi, H; Takeishi, Y; Yokokawa, T; Yoshihisa, A, 2013) |
| "We induced type 1 diabetes using streptozocin in 8-week-old Sprague-Dawley rats, divided them into two groups-a thalidomide treatment group (DM-T, n = 15) and a non-treatment group (DM-N, n = 15)-and compared them with a normal control (n = 10)." | 1.36 | The protective effect of thalidomide on left ventricular function in a rat model of diabetic cardiomyopathy. ( Chang, HJ; Chang, SA; Kim, DH; Kim, HK; Kim, HN; Kim, YJ; Lee, HW; Park, YB; Sohn, DW, 2010) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 2 (100.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Yokokawa, T | 1 |
| Nakazato, K | 1 |
| Kanno, Y | 1 |
| Mizukami, H | 1 |
| Kobayashi, A | 1 |
| Yoshihisa, A | 1 |
| Takahashi, H | 1 |
| Shichishima-Nakamura, A | 1 |
| Ohkawara, H | 1 |
| Noji, H | 1 |
| Suzuki, H | 1 |
| Saitoh, S | 1 |
| Ogawa, K | 1 |
| Hisa, S | 1 |
| Takeishi, Y | 1 |
| Kim, DH | 1 |
| Kim, YJ | 1 |
| Chang, SA | 1 |
| Lee, HW | 1 |
| Kim, HN | 1 |
| Kim, HK | 1 |
| Chang, HJ | 1 |
| Sohn, DW | 1 |
| Park, YB | 1 |
2 other studies available for thalidomide and Hypertrophy, Left Ventricular
| Article | Year |
|---|---|
Pulmonary hypertension and refractory heart failure in a patient with Crow-Fukase (POEMS) syndrome.
Topics: Aged; Dexamethasone; Diuretics; Drug Resistance; Edema; Furosemide; Heart Failure; Humans; Hypertens | 2013 |
The protective effect of thalidomide on left ventricular function in a rat model of diabetic cardiomyopathy.
Topics: Analysis of Variance; Animals; Antibiotics, Antineoplastic; Collagen; Diabetes Mellitus, Type 1; Dia | 2010 |